|Daily Range||$22.14 - $22.36|
|52-Week Range||$21.64 - $27.70|
|Dividend (Yield)||$0.00 (3.5%)|
|Average Daily Volume||37,677|
|Current FY EPS||$0.00|
Arena Pharmaceuticals takes the stage to highlight Belviq, other lorcaserin indications, and its remaining pipeline. Do investors have a reason to be excited?
The JPMorgan Healthcare Conference kicks off and Pharmacyclics dishes new pricing and duration data on key drug Imbruvica.
Sucampo's 8-K filing with the SEC delivers a nice surprise to shareholders.
These are the 10 countries with the longest life expectancy. See what factors have allowed their citizens to live longer as well as how you might be able to benefit from their longevity.
With Takeda's recent setback, Big Pharma's diabetes cupboard is looking very bare.
Concerns over infection risks spurred action from an FDA advisory panel regarding the approval of the inflammatory bowel disease treatment vedolizumab.
Big Pharma falters again, while an underrated CNS specialist delivers a new, better, drug
Is there any hope left for VIVUS, Arena, and Orexigen -- three obesity treatment stocks that increasingly appear to be addressing a demand that simply isn’t there?
A long-awaited safety data on a popular class of type 2 diabetes drugs sends mixed messages to doctors and investors.